Can GLP-1 Agonists Represent a Meaningful Therapeutic Option for People with Obstructive Sleep Apnea (OSA)?

Time: 9:30 am
day: Conference Day One


  • Discussing the clinical and economic burden of OSA
  • Understanding the basic pathophysiology of the disease and why GLP-1 RAs may be a valid treatment option
  • Evaluating the current treatment options for OSA and exploring the benefits GLP-1 RAs may bring
  • Reflecting on challenges and future plans to expand GLP-1 therapies into this area